Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ECE1 | P42892 | 2/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28581036 | 0.89 | MME (0.49) | ALDH1A1ADAMTS4MMP13NPC1RAB9A | |
| SCHEMBL27547818 | 0.86 | NPC1 (0.44) | ALDH1A1ADAMTS4MMP13NPC1RAB9A | |
| SCHEMBL27994897 | 0.83 | NPC1 (0.45) | ALDH1A1ADAMTS4MMP13NPC1RAB9A | |
| SCHEMBL1012491 | 0.83 | CA1 (0.53) | ALDH1A1NPC1RAB9AMMECA1 | |
| SCHEMBL721423 | 0.83 | CA1 (0.53) | ALDH1A1NPC1RAB9AMMECA1 | |
| SCHEMBL10659989 | 0.83 | CA1 (0.53) | ALDH1A1NPC1RAB9AMMECA1 | |
| SCHEMBL3741276 | 0.82 | NPC1 (0.41) | ALDH1A1ADAMTS4MMP13NPC1RAB9A | |
| SCHEMBL27388901 | 0.82 | NPC1 (0.41) | ALDH1A1ADAMTS4MMP13NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL857895 | 0.81 | CA1 (0.51) | ALDH1A1NPC1RAB9AMMECA1 | |
| SCHEMBL30547455 | 0.81 | ELANE (0.44) | ALDH1A1NPC1RAB9AECE1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759318-B2 | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | INHIBITEX, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2385951-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | University College Cardiff Consultants, Ltd. (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254856-A1 | MOBILE TERMINAL AND METHOD OF CONTROLLING OPERATION OF THE MOBILE TERMINAL | LG ELECTRONICS INC. (KR) | 2011-10-20 | — | — | US | disclosed |
| WO-2010081082-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| US-6017385-A | Ink compositions | XEROX CORPORATION (US) | 2000-01-25 | — | — | US | disclosed |
| US-5931995-A | Ink compositions | XEROX CORPORATION (US) | 1999-08-03 | — | — | US | disclosed |
| US-5051444-A | Pyrrolidine derivatives as anti-amnesia agents | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1991-09-24 | — | — | US | disclosed |
| US-4880827-A | Pyrrolidine derivatives having inhibitory action for proline specific endopepidase | SUMITOMO PHARMACEUTICALS COMPANY, LTD. (JP) | 1989-11-14 | — | — | US | disclosed |
| EP-0238319-A1 | Pyrrolidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1987-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | PNP, SAMHD1, MTAP | ALDH1A1 4139/4885ADAMTS4 3890/4885MMP13 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.